Results 151 to 160 of about 3,485 (208)

Postmarketing Surveillance of the Safety of Cyclic Etidronate

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1998
To evaluate the safety of cyclic etidronate in routine clinical practice, we obtained information from 550 general practices in the United Kingdom that provide the medical records to the General Practice Research Database. A group of 7977 patients taking cyclic etidronate and two age‐, gender‐, and practice‐matched control groups, one with osteoporosis
van Staa, T.P., Leufkens, H.G.M., Abenhaim, L., Cooper, C.   +3 more
core   +5 more sources

Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum

Atherosclerosis, 2020
Background and aims: In pseudoxanthoma elasticum (PXE), low levels of inorganic pyrophosphate result in extensive arterial calcification. Recently, the treatment of ectopic mineralization in the PXE (TEMP) trial showed that one year of treatment with ...
Pim A De Jong, Guido Kranenburg, Jelmer M Wolterink   +2 more
exaly   +2 more sources

Chemical, cytotoxic and genotoxic analysis of etidronate in sodium hypochlorite solution [PDF]

International Endodontic Journal, 2019
AIM To test whether the incorporation of a chelation powder, etidronate, marketed for root canal irrigation (Dual Rinse HEDP) into a sodium hypochlorite (NaOCl) solution induced additional cytotoxic and genotoxic effects not observed with NaOCl alone ...
Nidambur Vasudev Ballal, Matthias Zehnder, Dirk Mohn   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Etidronate and Osteoarthritis

JAMA: The Journal of the American Medical Association, 1991
To the Editor.— In the past 2 years I have been treating patients with osteoporosis with etidronate disodium. Patients are instructed to avoid dairy products, calcium supplements, and any other source of calcium on days 1 through 18. On days 4 through 18, the patient is instructed to take 200 mg of etidronate disodium twice a day; after day 18 the ...
openaire   +2 more sources

[Etidronate].

Nihon rinsho. Japanese journal of clinical medicine, 2003
Intermittent cyclical therapy with etidronate increases bone mineral density in spine and hip, and reduces the incidence of new vertebral fractures in women with postmenopausal osteoporosis, as well as steroid-induced osteoporosis. Seven years treatment with etidronate was reported to be safe, effective and well-tolerated.
Kentaro, Inui, Kunio, Takaoka
openaire   +1 more source

Treatment of Hyperparathyroidism With Etidronate Disodium

JAMA, 1983
THE DIPHOSPHONATES are synthetic inhibitors of skeletal resorption that have been used expermentally to treat hyperparathyroidism. 1-3 Much evidence has accumulated about the beneficial effect of the different forms of this class of drugs in normalizing the biochemical abnormalities of the disease, but there are few data about the clinical response of ...
A A, Licata, E, O'Hanlon
openaire   +2 more sources

Etidronate disodium in postmenopausal osteoporosis

Clinical Pharmacology & Therapeutics, 1976
Calcium‐balance, calcium‐kinetic, and physiologic observations were made in 10 osteoporotic patients treated for 6 to 12 mo with disodium etidronate (EHDP) in oral doses of 20 mg/kg/day. Absorption of EHDP averaged 10%, and effective retained dose was approximately 1.6 mg/kg/day.
R P, Heaney, P D, Saville
openaire   +2 more sources

Spontaneous Fractures in a Patient Treated with Low Doses of Etidronic Acid (Disodium Etidronate)

Drug Safety, 1992
The recommended regimen of etidronic acid (disodium etidronate) for the treatment of Paget's disease of bone is 5mg/kg/day for a period of less than six months. There have, however, been reports of impaired mineralisation of bone and concern that the risk of fracture is increased with this dosage.
K S, Eyres, P, Marshall, E, McCloskey, D L, Douglas, J A, Kanis   +4 more
openaire   +2 more sources

Clinical experience with etidronate in osteoporosis

Clinical Rheumatology, 1994
Clinical experience with cyclical etidronate for the treatment of osteoporosis was reviewed in 69 consecutive patients. Six patients stopped treatment either due to adverse effects (5) or the decision to take hormone replacement therapy (HRT) (1). Bone mineral density (BMD) measurements using dual energy X-ray absorptiometry (DXA) were obtained in 63 ...
P J, Ryan, I, Fogelman
openaire   +2 more sources

ETIDRONATE AND THE RISK OF FRACTURES

The Lancet, 1985
C, Nagant de Deuxchaisnes, J P, Dufour, J P, Devogelaer, J P, Huaux, W, Esselinckx   +4 more
openaire   +2 more sources